By Michal Kasprowicz and Sangeetha Punniyamoorthy

Due to the coronavirus disease 2019 (COVID-19) pandemic there have been recent amendments to Canada’s Patent Act that will authorize the use of certain patented inventions necessary to respond in a public health emergency. These measures will authorize the manufacturing and distribution of patented
Continue Reading COVID-19’s Impact on Canadian patent owners

Trial and error – with the vast majority of trials ending in error – has long been the default method of drug discovery. Of the USD2.6 billion spent each year on drug discovery by the world’s largest pharmaceutical companies, at least nine-tenths will go toward funding drug research that will
Continue Reading The error of trials: Legal considerations when deploying AI in drug development